粉样β酸:有罪的指控?
M Paul Murphy1, Valeria A Buzinova1, Carrie E Johnson1
1Department of Molecular and Cellular Biochemistry and the Sanders-Brown Center on Aging University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536, USA.
Biochimica et biophysica acta. Molecular basis of disease
|November 7, 2023
概括
最近针对粉样β (Aβ) 的阿尔茨海默病疗法在减缓进展方面表现出适度的有效性. 然而,完全去除Aβ并不能阻止疾病,这对粉样蛋白级联假设构成了难题.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 直到最近,阿尔茨海默病 (AD) 领域在开发疾病修饰疗法方面取得的进展有限.
- 粉样蛋白级联假设认为,粉样蛋白β (Aβ) 积累是AD病变发生的主要驱动因素.
- 针对Aβ的单克隆抗体已经成为一种潜在的治疗策略.
研究的目的:
- 审查最近关于阿尔茨海默病抗粉样β (Aβ) 治疗方法的进展和争议.
- 在临床试验中评估Aβ向疗法的疗效.
- 为了解决Aβ去除和完全停止疾病之间的差异.
主要方法:
- 对针对Aβ的单克隆抗体最近临床试验结果的分析.
- 关于粉样蛋白级联假设和AD病变的科学文献的综述.
- 讨论当前治疗结果对理解AD的影响.
主要成果:
- 一些针对Aβ的单克隆抗体在减缓阿尔茨海默病进展方面表现出适度的有效性.
- 多种抗Aβ疗法正在接近或已经获得监管部门的批准.
- 尽管去除了Aβ,但疾病的进展并没有完全停止,这表明疾病机制复杂.
结论:
- 准β-粉样蛋白去除代表着在阿尔茨海默病治疗方面取得了显著的,虽然不是完全的,治疗进展.
- 部分Aβ清除疗法的有效性挑战了对粉样蛋白级联假设的简单观点.
- 需要进一步的研究来阐明Aβ的确切作用,并确定AD的额外治疗点.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.7K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.3K
相关概念视频
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498